Gene editing company Precision BioSciences Inc (NASDAQ: DTIL) announced on Monday that it has submitted Clinical Trial Applications (CTA) for PBGENE-HBV, marking the first gene-editing approach targeting chronic hepatitis B virus (HBV).
PBGENE-HBV is designed to eliminate cccDNA, the root cause of HBV replication, while inactivating integrated HBV DNA in hepatocytes.
This proprietary gene-editing program, powered by the company's ARCUS platform, is aimed at potentially curing HBV. Precision expects to share safety data and Phase 1 plans in November, ahead of the American Association for the Study of Liver Diseases (AASLD) Annual Meeting.
Chronic HBV affects over 300 million people globally, with no curative treatments currently available. PBGENE-HBV seeks to address this need by offering a highly specific and novel therapeutic approach that targets the core drivers of the disease, potentially leading to functional cures.
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma